Latest News about RHHBY
Recent news which mentions RHHBY
Merck's Crown Jewel Cancer Drug Keytruda Scores FDA Approval For Third Indication In Cervical Cancer
January 16, 2024
From Benzinga
Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference
January 10, 2024
From Benzinga
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
January 09, 2024
From Motley Fool
Why Is LumiraDx (LMDX) Stock Down 13% Today?
January 08, 2024
From InvestorPlace
3 Great Foreign Companies to Invest in Right Now
January 08, 2024
From Motley Fool
Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M
January 02, 2024
From Benzinga
Weighing Their Chances: 5 Leading Healthcare Companies Fight for Market Share in the $100 Billion Weight-Loss Industry
December 21, 2023
From Motley Fool
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
December 21, 2023
From Benzinga
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know
December 20, 2023
From Motley Fool
Weight-Loss Drug Gold Rush Gets Larger As New Player Fractyl Health Files For $100M IPO
December 15, 2023
From Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in December
December 15, 2023
From InvestorPlace
Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial
December 11, 2023
From Benzinga
Why Viking Therapeutics Was Crushing It This Week
December 08, 2023
From Motley Fool
From MarketWatch
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
December 06, 2023
From Benzinga
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
December 05, 2023
From Benzinga
Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation
December 05, 2023
From Benzinga
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
December 04, 2023
From Benzinga
From Benzinga
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
December 04, 2023
From Benzinga
Ignore Crypto: These Stocks Could Make You Rich
November 23, 2023
From Motley Fool
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
November 17, 2023
From InvestorPlace
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
November 16, 2023
From Benzinga
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
November 10, 2023
From Motley Fool
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug
November 02, 2023
From Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
October 31, 2023
From Benzinga
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
October 28, 2023
From Benzinga
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
October 28, 2023
From Motley Fool
From Motley Fool
Why Is Roivant Sciences (ROIV) Stock Up Today?
October 23, 2023
From InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.